Geron: Hold Rating Amid EU Launch Challenges and CEO Transition

H.C. Wainwright analyst Emily Bodnar has reiterated their neutral stance on GERN stock, giving a Hold rating on February 26.

Emily Bodnar’s rating is based on several factors influencing Geron’s current market position. The recent approval of Rytelo in the EU, while expanding potential revenue streams, aligns with prior expectations and does not serve as a significant catalyst due to the lengthy launch process involving patient access, pricing, and reimbursement challenges. The anticipated 2026 launch in the EU was already factored into the investment thesis, and the focus remains on the US market where recent revenue commentary has been flat.
Additionally, the departure of Geron’s long-time CEO, John “Chip” A. Scarlett, adds an element of uncertainty, although the company is actively seeking a replacement with substantial commercial experience. The interim leadership and the unchanged commercial strategy suggest stability, but the need for a new CEO to drive sales in earlier line settings remains crucial. These developments, while noteworthy, do not alter the existing investment thesis, leading to the Hold rating as the company navigates these transitions and awaits future revenue assessments.

In another report released on February 26, B.Riley Financial also downgraded the stock to a Hold with a $2.00 price target.